Most linked-to pages

Showing below up to 50 results in range #51 to #100.

51. Perillyl Alcohol/Limonene‏‎ (3 links)
52. Proton Pump Inhibitors (e.g., Lansoprazole, Nexium)‏‎ (3 links)
53. Sodium R Lipoate and Hydroxycitrate (METABLOC)‏‎ (3 links)
54. This vaccine represents a promising strategy by targeting CMV antigens present in GBM cells, potentially extending survival significantly beyond standard treatments. Initial results suggest substantial benefits for certain patient groups.‏‎ (3 links)
55. VT-122‏‎ (3 links)
56. VT-122 (Propranolol and Etodolac combination)‏‎ (3 links)
57. Valproic Acid/Sodium Valproate (Depakote)‏‎ (3 links)
58. Property:Has OS with‏‎ (3 links)
59. Property:Has OS without‏‎ (3 links)
60. Property:Has PFS with‏‎ (3 links)
61. Property:Has PFS without‏‎ (3 links)
62. MediaWiki:Smw import foaf‏‎ (3 links)
63. Data not specified‏‎ (3 links)
64. Phase II‏‎ (3 links)
65. 14-16 months with standard treatment.‏‎ (2 links)
66. 16 months (control group in EF-14 Trial)‏‎ (2 links)
67. 17% in the study of patients with tumors recurring after radiation; 38% in a study using PCV for tumors recurrent after radiation (and for some after prior chemotherapy); 13% in a study with PCV after Temodar failure‏‎ (2 links)
68. 20.9 months (Optune plus temozolomide, final EF-14 analysis)‏‎ (2 links)
69. 5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.‏‎ (2 links)
70. 8.0 months mOS observed in phase 2 trial for patients receiving treatment dose of 30 mg/m2/day‏‎ (2 links)
71. ABT-414‏‎ (2 links)
72. Accutane‏‎ (2 links)
73. Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine‏‎ (2 links)
74. Angiotensin-II Receptor Blockers (ARB)‏‎ (2 links)
75. Anlotinib‏‎ (2 links)
76. Anti-CMV Dendritic Cell Vaccine‏‎ (2 links)
77. Based on available data, potentially highly useful in specific dosing schedules‏‎ (2 links)
78. CBG‏‎ (2 links)
79. Celebrex‏‎ (2 links)
80. Chronotherapy‏‎ (2 links)
81. Chronotherapy with Temozolomide (TMZ)‏‎ (2 links)
82. Comparable to standard treatment, specifics depend on individual patient factors.‏‎ (2 links)
83. Curcumin‏‎ (2 links)
84. Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.‏‎ (2 links)
85. Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma‏‎ (2 links)
86. Dendritic Cell Vaccine (DCVax-L)‏‎ (2 links)
87. Disulfiram‏‎ (2 links)
88. Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy‏‎ (2 links)
89. Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts‏‎ (2 links)
90. Ellagic acid‏‎ (2 links)
91. Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates‏‎ (2 links)
92. GLA‏‎ (2 links)
93. Garlic‏‎ (2 links)
94. Gleevec (Imatinib)‏‎ (2 links)
95. High-dose PBT showed a median OS of 65.6 months for patients with radiation necrosis, and 26.9 months for patients without radiation necrosis in specific studies‏‎ (2 links)
96. Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM.‏‎ (2 links)
97. Historical controls suggest a median overall survival of 20-35% at 12 months for similar populations.‏‎ (2 links)
98. Historical mOS for similar patient population using lomustine is 7.2 months‏‎ (2 links)
99. Hyperthermia‏‎ (2 links)
100. ICT-107‏‎ (2 links)